Therapeutic interventions for sleep disorders in Parkinson's disease
References
Additional references
Carter J, Carroll S, Lannon MC. Sleep disruption in untreated Parkinson's disease. Neurology 1990;40(suppl 1):220.
Factor SA, McAlarney T, Sanchez‐Ramos JR, Weiner WJ. Sleep disorders and sleep effect in Parkinson's disease. Movement Disorders 1990;5:280‐5.
Ferreira JJ, Desboeuf K, Galitzky M, Thalamas C, Brefel‐Courbon C, Fabre N, et al. Sleep disruption, daytime somnolence and 'sleep attacks' in Parkinson's disease: a clinical survey in PD patients and age‐matched healthy volunteers. European Journal of Neurology 2006;13(3):209‐14.
Jansen EN, Meerwaldt JD. Madopar HBS in Parkinson patients with nocturnal akinesia. Clinical Neurology and Neurosurgery 1988;90(1):35‐9.
Karlsen KH, Larsen JP, Tandberg E, Maeland JG. Influence of clinical and demographic variables on quality of life in patients with Parkinson's disease. Journal of Neurology Neurosurgery and Psychiatry 1999;66(4):431‐5.
Leeman AL, O'Neill CJ, Nicholson PW, Deshmukh AA, Denham MJ, Royston JP, et al. Parkinson's disease in the elderly: response to and optimal spacing of night time dosing with levodopa. British Journal of Clinical Pharmacology 1987;24(5):637‐43.
Lees AJ. A sustained‐release formulation of L‐dopa (Madopar HBS) in the treatment of nocturnal and early‐morning disabilities in Parkinson's disease. European Neurology 1987;27(suppl 1):126‐34.
Lees AJ, Blackburn NA, Campbell VL. The night time problems of Parkinson's disease. Clinical Neuropharmacology 1988;11:512‐9.
Lesser RP, Fahn S, Snider SR, Cote LJ, Isgreen WP, Barrett RE. Analysis of the clinical problems in parkinsonism and the complications of long‐term levodopa therapy. Neurology 1979;29(9 Pt 1):1253‐60.
Nausieda PA, Weiner WJ, Kaplan LR, Weber S, Klawans HL. Sleep disruption in the course of chronic levodopa therapy: an early feature of the levodopa psychosis. Clinical Neuropharmacology 1982;5(2):183‐94.
Parkinson J. An essay on the shaking. London: Whittingham and Rowland, 1817.
Reuter I, Ellis CM, Ray Chaudhuri K. Nocturnal subcutaneous apomorphine infusion in Parkinson's disease and restless legs syndrome. Acta Neurologica Scandinavica 1999;100:163‐7.
Stocchi F, Barbato L, Nordera G, Berardelli A, Ruggieri S. Sleep disorders in Parkinson's disease. Neurology 1998;245 (suppl 1):S15‐8.
Sweet RD, McDowell FH. Five years' treatment of Parkinson's disease with levodopa. Therapeutic results and survival of 100 patients. Annals of Internal Medicine 1975;83(4):456‐63.
Tandberg E, Larsen JP, Karlsen K. A community‐based study of sleep disorders in patients with Parkinson's disease. Movement Disorders 1998;13:895‐9.
Twelves D, Perkins K, Counsell C. Systematic review of incidence studies of Parkinson's disease. Movement Disorders 2003;8(1):19‐31.
UK Madopar CR Study Group. A comparison of Madopar CR and standard Madopar in the treatment of nocturnal and early‐morning disability in Parkinson's disease. Clinical Neuropharmacology 1989;12(6):498‐505.
Van Den Eeden SK, Tanner CM, Bernstein AL, Fross RD, Leimpeter A, Bloch DA, et al. Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. American Journal of Epidemiology 2003;157(11):1015‐22.
Van den Kerchove M, Jacquy J, Gonce M, De Deyn PP. Sustained‐release levodopa in parkinsonian patients with nocturnal disabilities. Acta Neurologica Belgica 1993;93(1):32‐9.
van Hilten JJ, Weggeman M, van der Velde EA, Kerkhof GA, van Dijk JG, Roos RAC. Sleep, excessive daytime sleepiness and fatigue in Parkinson's disease. Journal of Neural Transmission 1993;5:235‐44.
